Why the study?
Pure native aortic regurgitation presents unique structural challenges distinct from aortic stenosis, prompting a review of current evidence and challenges for TAVI in this off-label setting.
Does transcatheter aortic valve implantation (TAVI) improve outcomes in patients with pure native aortic regurgitation?
Does transcatheter aortic valve implantation (TAVI) improve outcomes in patients with pure native aortic regurgitation?
TAVI for pure native aortic regurgitation presents unique anatomical challenges compared to aortic stenosis, though early evidence shows promise with both dedicated and non-dedicated devices.
Off-label TAVI in native aortic regurgitation requires anatomical caution; leaves open need for dedicated devices and trials.
Treatment of degenerative aortic stenosis has been transformed by transcatheter aortic valve implantation (TAVI) over the past 10-15 years. The success of various technologies has led operators to attempt to broaden the indications, and many patients with native valve aortic regurgitation have been treated 'off label' with similar techniques. However, the alterations in the structure of the valve complex in pure native aortic regurgitation are distinct to those in degenerative aortic stenosis, and there are unique challenges to be overcome by percutaneous valves. Nevertheless some promise has been shown with both non-dedicated and dedicated devices. In this article, the authors explore some of these challenges and review the current evidence base for TAVI for aortic regurgitation.
No takes yet. Share an insight, caveat, or question.
Arias et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: